|3.32||-0.0800||-2.35%||Vol 786.44K||1Y Perf -34.87%|
|Jun 28th, 2022 16:00 DELAYED|
|- -||-0.02 -0.60%|
|Target Price||7.33||Analyst Rating||Moderate Buy 2.50|
|Potential %||120.78||Finscreener Ranking||★★★ 48.48|
|Insiders Trans % 3/6/12 mo.||-/-/67||Value Ranking||★★ 46.03|
|Insiders Value % 3/6/12 mo.||-/-/99||Growth Ranking||★★+ 49.27|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/99||Income Ranking||— -|
|Price Range Ratio 52W %||13.59||Earnings Rating||Sell|
|Market Cap||500.68M||Earnings Date||8th Aug 2022|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Aug 2022|
|Estimated EPS Next Report||0.17|
|EPS Growth Next 5 Years %||25.00|
|Avg. Weekly Volume||628.16K|
|Avg. Monthly Volume||682.24K|
|Avg. Quarterly Volume||738.17K|
Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 3.4 per share at the end of the most recent trading day (a 6.25% change compared to the prior day closing price) with a volume of 425.34K shares and market capitalization of 500.68M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 5500 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.
The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is -34.87%, while year-to-date (YTD) performance is -29.02%. AMRX stock has a five-year performance of -79.01%. Its 52-week range is between 2.9 and 5.99, which gives AMRX stock a 52-week price range ratio of 13.59%
Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of 160.00, a price-to-book (PB) ratio of 1.23, a price-to-sale (PS) ratio of 0.24, a price to cashflow ratio of 2.30, a PEG ratio of 2.32, a ROA of 0.05%, a ROC of 2.56% and a ROE of 0.51%. The company’s profit margin is -0.07%, its EBITDA margin is 18.00%, and its revenue ttm is $2.10 Billion , which makes it $13.91 revenue per share.
Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.17 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Moderate Buy (2.5), with a target price of $7.33, which is +120.78% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amneal Pharmaceuticals Inc. Class A has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.14, ATR14 : 0.21, CCI20 : 17.54, Chaikin Money Flow : 0.09, MACD : -0.09, Money Flow Index : 50.64, ROC : 1.80, RSI : 51.85, STOCH (14,3) : 86.93, STOCH RSI : 1.00, UO : 48.79, Williams %R : -13.07), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Anastasios G. Konidaris (Option Excercise at a value of $0), Andrew S. Boyer (Option Excercise at a value of $0), Chintu Patel (Buy at a value of $1 251 000), Chirag Patel (Buy at a value of $1 251 000), Emily Peterson Alva (Option Excercise at a value of $0), Gautam Patel (Buy at a value of $421 000), Gautam Patel (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jeffrey P. George (Option Excercise at a value of $0), John J. Kiely (Option Excercise at a value of $0), Joseph Todisco (Option Excercise at a value of $0), Nikita Shah (Option Excercise at a value of $0), Nikita Shah (Sold 4 000 shares of value $15 800 ), Paul M. Meister (Option Excercise at a value of $0), Shlomo Yanai (Option Excercise at a value of $0), Ted C. Nark (Option Excercise at a value of $0)
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.